AstraZeneca reports detailed results from CAPItello-291 Phase 3 trial

Detailed results from the CAPItello-291 Phase 3 trial showed AstraZeneca’s capivasertib in combination with Faslodex demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, or PFS, versus placebo plus Faslodex in patients with hormone receptor-positive, HER2-low or negative, locally advanced or metastatic breast cancer, following recurrence or progression on, or after, endocrine therapy, AstraZeneca announced. Results showed capivasertib in combination with Faslodex demonstrated a 40% reduction in the risk of disease progression or death versus placebo plus Faslodex in the overall trial population. In the AKT pathway biomarker-altered population, capivasertib plus Faslodex reduced the risk of disease progression or death by 50% versus placebo plus Faslodex. Alterations within the AKT pathway occur frequently in breast cancer, affecting up to 50% of patients with advanced HR-positive breast cancer. Results will be presented today in an oral presentation at the 2022 San Antonio Breast Cancer Symposium, or SABCS.